Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

Influenza Other Respir Viruses. 2017 Mar;11(2):157-164. doi: 10.1111/irv.12431. Epub 2016 Dec 30.

Abstract

Background: Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality.

Objectives: To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection.

Patients/methods: In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season.

Results: The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively.

Conclusions: Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered.

Keywords: Down syndrome; hospitalization; palivizumab; prospective birth cohort study; respiratory syncytial virus.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease / epidemiology
  • Antiviral Agents / therapeutic use
  • Down Syndrome / complications*
  • Down Syndrome / epidemiology
  • Down Syndrome / virology*
  • Epidemiologic Studies*
  • Female
  • Follow-Up Studies
  • Hospitalization / statistics & numerical data*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Palivizumab / therapeutic use
  • Prospective Studies
  • Respiratory Syncytial Virus Infections / complications*
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / epidemiology*
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Virus, Human / isolation & purification
  • Risk Factors

Substances

  • Antiviral Agents
  • Palivizumab